| Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. | |
| | |
MedLine Citation:
|
PMID: 15683605 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ischemic heart disease is characterized by a modification of the normal energy balance of the heart. During and following an ischemic event, circulating fatty acids are elevated, resulting in the acceleration of fatty acid oxidation at the expense of glucose oxidation. Despite the reduction in glucose oxidation, the rate of glycolysis increases, leading to an uncoupling of glucose metabolism. This results in the accumulation of metabolic byproducts, which leads to a decrease in cardiac efficiency. A novel therapeutic strategy involves improving the efficiency of oxygen utilization by the ischemic heart by the modulation of energy metabolism. This can be achieved by a reduction in the levels of circulating fatty acids using beta-blockers, glucose-insulin-potassium infusions, and nicotinic acid. Alternatively, fatty acid oxidation can be directly inhibited using trimetazidine, ranolazine, or glucose oxidation directly activated using dichloroacetate, which significantly improves the efficiency of the heart. |
| | |
Authors:
|
Clifford D L Folmes; Alexander S Clanachan; Gary D Lopaschuk |
Related Documents
:
|
16269705 - Abundance, activity, and community structure of pelagic methane-oxidizing bacteria in t... 7137365 - Effect of thyroxine treatment on exogenous myocardial lactate oxidation. 7763255 - Adrenoleukodystrophy: the restoration of peroxisomal beta-oxidation by transfection of ... 2565735 - Activities of enzymes of lipid metabolism in morris hepatoma 7800 c1 cells. 15177755 - Tuning the diffusion dialysis performance by surface cross-linking of ppo anion exchang... 10630125 - Fukiic and piscidic acid esters from the rhizome of cimicifuga racemosa and the in vitr... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current atherosclerosis reports Volume: 7 ISSN: 1523-3804 ISO Abbreviation: Curr Atheroscler Rep Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2005-02-01 Completed Date: 2005-06-30 Revised Date: 2005-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 100897685 Medline TA: Curr Atheroscler Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 63-70 Citation Subset: IM |
Affiliation:
|
Cardiovascular Research Group, University of Alberta, Edmonton, Alberta T6G 2S2, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carbohydrate Metabolism Energy Metabolism Enzyme Inhibitors / therapeutic use Fatty Acids / metabolism* Humans Myocardial Ischemia / metabolism Myocardial Reperfusion Injury / metabolism Myocardium / metabolism Oxidation-Reduction / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Fatty Acids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Adipocytokines: emerging therapeutic targets.
Next Document: Antioxidants and atherosclerosis: emerging drug therapies.